Raymond James & Associates Sangamo Therapeutics, Inc Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$0.36 - $0.65 $252 - $455	-700 Reduced 5.02%	13,250 $4,000
Q1 2024 Apr 22, 2024	BUY	$0.42 - $1.38 $5,859 - $19,251	13,950 New	13,950 $9,000
Q4 2021 Feb 08, 2022	SELL	$7.29 - $10.97 $106,324 - $159,997	-14,585 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$9.01 - $12.01 $816,756 - $1.09 Million	-90,650 Reduced 86.14%	14,585 $131,000
Q2 2021 Aug 11, 2021	BUY	$10.17 - $12.64 $102,869 - $127,853	10,115 Added 10.63%	105,235 $1.26 Million
Q1 2021 May 14, 2021	BUY	$10.88 - $17.05 $186,048 - $291,555	17,100 Added 21.92%	95,120 $1.19 Million
Q4 2020 Feb 12, 2021	BUY	$9.23 - $18.18 $720,124 - $1.42 Million	78,020 New	78,020 $1.22 Million
Q2 2018 Aug 14, 2018	SELL	$13.9 - $19.8 $189,415 - $269,814	-13,627 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$16.7 - $26.35 $227,570 - $359,071	13,627 New	13,627 $259,000

135

86.5M

35.9K

156K

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $319M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.